Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 70 people, planned
- Starts
- Dec 2026
- Expected to end
- Mar 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Propranolol
- Psychotherapy
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Women aged from 18 to 75 years
- Having been victim of severe violence (rape, sexual assault, physical assault) Currently suffering from PTSD related to the traumatic event. The diagnosis of PTSD is made according to the DSM-5 criteria by a psychiatrist/psychologist using the CAPS-5, regardless of the traumatic event meeting criterion A of the DSM-5, with or without dissociative symptoms as described in the "With dissociative symptoms" section of the DSM-5, Immediate or delayed PTSD CAPS-5 total score ≥ 33 heart rate ≥ 55 bpm
- The subject must have signed the consent form
- The subject must be enrolled in a social security program
- The participant must be able to understand and read French
- The participant agrees to comply with the contraception requirements outlined in the protocol
Who cannot take part
- Previous intolerance to a beta-blocker
- Undergoing psychotherapy or pharmacological treatment with psychotropic agents such as antidepressants, neuroleptics, and/or mood stabilizers. However, these subjects may be included after a 2-week therapeutic abstinence period (6 weeks for treatment with fluoxetine)
- Contraindications to the administration of propranolol: Asthma, Chronic obstructive pulmonary disease, Decompensated heart failure, Cardiogenic shock, Unpaced second-degree atrioventricular block, Unpaced third-degree atrioventricular block, Spasmodic angina, Uncompensated sinus node dysfunction, bradycardia, Raynaud's syndrome, severe peripheral circulatory disorder, untreated pheochromocytoma, arterial hypotension, hypersensitivity to beta-blockers, history of anaphylactic allergic reaction
- Heart failure (compensated or decompensated)
- Severe liver disease
- Significant renal impairment
- Personal or family history of psoriasis
- Severe psychiatric disorders: Severe symptoms of other anxiety disorders, severe symptoms of Obsessive-Compulsive Disorder, history of or current psychotic disorder, bipolar mood disorder, severe personality disorder, alcohol or other substance use disorder
- Women of childbearing age not using contraception
- Systolic blood pressure below 100 mm Hg
- Myasthenia gravis
- Patients who have suffered a head injury within the past year or who have clinical symptoms and residual neurological sequelae
- Wearing contact lenses
- "Yes" response to item 4 of the C-SSRS: active suicidal ideation with intent to act, without a specific plan, and/or "Yes" response to item 5 of the C-SSRS: active suicidal ideation with a specific plan and intent to act
- Hospitalized or treated for suicidal behavior within the past 3 months
- Pregnancy, breastfeeding
- Current use of a beta-blocker, regardless of the formulation
- Known interactions with Propranolol (combination use not recommended and combinations to be used with caution) as indicated in the summary of product characteristics
- Patients under judicial protection, under guardianship or curatorship, individuals under family authorization, or under a future protection order with representation regarding the person
- Participants who are related to a person involved in the study at the investigator's center, within the clinical research organization (CRO), or at the sponsor
- Participation in another interventional research study, clinical trial, or clinical investigation within the 6 months preceding selection
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Post-traumatic stress disorder (PTSD) develops after life-threatening events, with domestic violence and sexual assault being major risk factors. An innovative approach using traumatic memory reactivation with propranolol has shown promise in reducing PTSD symptoms. This study aims to compare the efficacy of propranolol with trauma-focused psychotherapy in women suffering from severe PTSD after violence.
The 2 groups in the trial
- Propranolol groupTreatment being tested
Treatment: Propranolol
- Psychotherapy groupExisting treatment, for comparison
Treatment: Psychotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Fit questions
- Built from NCT07792122, who can take part
- Record updated
- 6 November 2026